^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RX108

    i
    Other names: RX108
    Associations

    News

    Trials
    Company:
    Suzhou NeuPharma
    Drug class:
    Na+-K+ ATPAse inhibitor
    Associations

    News

    Trials
    over2years
    Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer (ACTRN12623000307606)
    P1, N=20, Recruiting, NeuPharma Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Metastases
    |
    RX108
    over2years
    Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer (ACTRN12623000307606)
    P1, N=20, Recruiting, NeuPharma Pty Ltd
    New P1 trial • Metastases
    |
    RX108
    3years
    Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. (PubMed, Mol Cancer Ther)
    Taken together, these findings reveal a novel approach to target glutamine metabolism through inhibiting Na+/K+-ATPase and provide a rationale for using RX108 to treat HCC in patients whose tumors express ASCT2 at high levels. RX108 is currently under clinical development.
    Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    |
    RX108